The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

DiagnoCure to host Q4 2012 and full year earnings conference call and webcast

Monday, January 07, 2013

DiagnoCure to host Q4 2012 and full year earnings conference call and webcast07:30 EST Monday, January 07, 2013 QUEBEC CITY, Jan. 7, 2013 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR) announced today that the Corporation will release its fourth quarter and fiscal  year 2012 operating results on January 11, 2013, at 4:00 p.m. (EST). DiagnoCure's management will host a conference call the same day, at 4:30 p.m. (EST). Interested participants may listen to the call by dialing 1-888-231-8191 or 514-807-9895 and referencing code 86003400 approximately 15 minutes prior to the call. The Corporation will also provide a live webcast of the call. Interested participants may access the webcast on DiagnoCure's website at, through a link on the Investors page - Presentations. A replay of the webcast will be available on DiagnoCure's website for those unable to participate in the live webcast. About DiagnoCure DiagnoCure (TSX: CUR) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched the PrevistageTM GCC Colorectal Cancer Staging Test through its U.S. CLIA laboratory, and granted the worldwide exclusive rights to this test to Signal Genetics in June 2011. The Corporation has also granted a worldwide exclusive license agreement to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. (NASDAQ: HOLX) operating as Hologic Gen-Probe, for the development and commercialization of a prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. Gen-Probe's PROGENSA® PCA3 test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States. For more information, visit Forward-looking statements This release contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein unless required by the applicable securities laws and regulations. SOURCE DIAGNOCURE INC.For further information: <p> </p> <p> <b><u>Investors</u></b><br/> <b>DiagnoCure Inc.</b><br/> Chantal Miklosi<br/> Chief Financial Officer<br/> (418) 527-6100<br/> <a href=""></a><br/> <br/> <b><u>Media</u></b><br/> <b>DiagnoCure Inc.</b><br/> Geneviève Couture<br/> Coordinator, Administration and Communications<br/> (418) 527-6100<br/> <a href=""></a><br/> </p>